ARCHIVES

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 13 | March 30, 2001

Download PDF Visit The Full Archive

Related Articles

AACR Meeting: Celebrex Studies Show Benign Polyp Reduction, Point To Challenges In Biomarker Validation.

April 14, 2006

New Predictive Score May Help In Planning Adjuvant Therapy

September 26, 2008

Broad Institute wins NIH grant for first national SNP genotyping center.

October 8, 2004

Interferon Interest Zooms; NCI Awarding Production Contracts, Proceeds With Plans For Clinical Trials

March 14, 1980

In Brief: NCI Will Stop Free Group C distribution Of VP-16 Sept. 1 Unless Bristol Supplies It At No Charge

June 25, 1982

NCI 1985 Bypass Budget By Groups

May 20, 1983